Patients with decompensated hepatitis B virus (HBV) cirrhosis have a poor prognosis due to the development of progressive liver failure and hepatocellular carcinoma. Lamivudine appears to be a ...
Sarcopenia is a common complication of decompensated cirrhosis resulting in progressive loss of muscle mass and function. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
12d
Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast ...
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC ...
These features make lamivudine a more appropriate treatment compared with IFN for patients with decompensated HBV cirrhosis. The recommended dose of lamivudine is 100 mg daily. Because lamivudine ...
According to National Institutes of Health, decompensated cirrhosis is an acute deterioration in liver function in a patient with cirrhosis. Fast Track Designation provides several benefits ...
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback